Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL3172901 | 1.00 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL27927313 | 0.99 | ABCB11 (0.96) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL5567933 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031641 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL754557 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL30388817 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031319 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL14009483 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120037248-A | Medicament for simultaneously reducing bleeding and microvascular obstruction risks | 中国科学院上海药物研究所 | 2025-05-27 | — | — | CN | claimed |
| CN-115598261-B | Method for measuring related substances in raw material and preparation of clopidodine hydrochloride | 地奥集团成都药业股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118845782-A | Application of ZINC62678696 in preventing and treating pneumonia | 广州市妇女儿童医疗中心 | 2024-10-29 | — | — | CN | claimed |
| CN-115845065-A | Use of FN/FAK pathway inhibitor in preparation of medicine for improving thyroid cancer radioiodine treatment sensitivity | 江苏省原子医学研究所 | 2023-03-28 | — | — | CN | claimed |
| CN-113288878-B | Cloperidine hydrochloride tablet and preparation method thereof | 地奥集团成都药业股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115598261-A | Method for determining hydrochloride cloperastine raw material and related substances in preparation thereof | 地奥集团成都药业股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-111380982-B | Method for detecting content of 2-chloroethanol in cloperamide hydrochloride raw material | 重庆市食品药品检验检测研究院 | 2022-10-14 | — | — | CN | claimed |
| CN-114822876-A | Model, apparatus and storage medium for predicting drug absorption rate constant | 湖南慧泽生物医药科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-113384702-A | Application of H1 histamine receptor antagonist in preparation of medicine for treating glioma | 温州医科大学附属第一医院 | 2021-09-14 | — | — | CN | claimed |
| CN-107118221-B | Preparation method of clopidogrel hydrogen sulfate crystal form I | 常州制药厂有限公司 | 2021-09-07 | — | — | CN | claimed |
| WO-2007029080-A1 | PREPARATION OF FORM I OF CLOPIDOGREL HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (US) | 2007-03-15 | — | — | WO | claimed |
| WO-2007029096-A2 | NOVEL POLYMORPHIC FORMS OF CLOPIDOGREL HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | claimed |
| US-20070048370-A1 | Pharmaceutical formulation for salts of monobasic acids with clopidogrel | HELM AG (DE) | 2007-03-01 | — | — | US | claimed |
| EP-1750701-A1 | AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE | IVAX Pharmaceuticals s.r.o. (CZ) | 2007-02-14 | — | — | EP | claimed |
| CN-1903859-A | Method of preparing chloropy gra hydrogen sulphate type I | SHANGHAI COLLEGE OF APPLIED TE (CN) | 2007-01-31 | — | — | CN | claimed |
| EP-1740593-A1 | PROCESSES FOR THE PREPARATION OF CLOPIDOGREL HYDROGEN SULFATE POLYMORPHIC FORM I | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2007-01-10 | — | — | EP | claimed |
| CN-1850827-A | Method for preparing (+)-(s-)-clopiclogrel hydrogensulfate (I) | ZHEJIANG HAIXIANG PHARMACEUTIC (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1840533-A | Process for synthesizing I-clopidogrel hydrogen sulfate | SHANGHAI INST TECHNOLOGY (CN) | 2006-10-04 | — | — | CN | claimed |
| WO-2005117866-A1 | AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2005-12-15 | — | — | WO | claimed |
| WO-2005100364-A1 | PROCESSES FOR THE PREPARATION OF CLOPIDOGREL HYDROGEN SULFATE POLYMORPHIC FORM I | KRKA, TOVARNA ZDRAVIL, D.D. NOVO MESTO (SI) | 2005-10-27 | — | — | WO | claimed |